Men’s Health Company Rugiet Expands Into Testosterone Therapy After Surpassing $100 Million in Revenue

The new TRT program and brand identity marks the next chapter for the company that has treated more than 400,000 patients with its performance-driven health solutions

AUSTIN, Texas--(BUSINESS WIRE)--Rugiet, a men’s health company, today announced the launch of its testosterone replacement therapy (TRT), marking a significant expansion beyond its flagship erectile dysfunction treatments. The company, which surpassed $100 million in revenue in 2025, also introduced a new brand identity with the launch, signaling its evolution into a broader performance-driven healthcare company for men.

The therapy options include enclomiphene as well as oral, injectable, and topical testosterone replacement therapy, supported by comprehensive lab testing, physician evaluations, and individualized treatment plans for qualified patients.

Best known for its novel 3-in-1 erectile dysfunction treatment, Ready®, Rugiet’s science-backed solutions have been at the forefront of men’s health since 2020. As the company scaled, it identified a growing intersection between psychological and physiological health, which has informed solutions that deliver innovative care and tackle underlying health issues.

“Hundreds of thousands of men trust Rugiet to help them with their performance in the bedroom, which has uncovered additional areas of health that often go hand-in-hand with erectile dysfunction and often signal broader health issues,” said Mike Apostal, CEO of Rugiet. “Entering testosterone therapy is a natural next step for us as we build a singular destination for men looking to take control of their health.”

Research published in The Journal of Clinical Endocrinology & Metabolism has documented generational declines in testosterone levels, independent of aging. Separately, a 2024 study published in PLoS One found that prescription of testosterone treatments increased significantly among younger men. Rugiet's proven model of accessible, clinician-guided care — already trusted across multiple areas of men's health — now extends to testosterone, where personalized treatment has been long overdue.

“As testosterone becomes more mainstream, the opportunity to transform the standard for the modern TRT experience becomes more apparent,” said Dr. Nicholas Farber, a urologist specializing in men’s health and sexual medicine and a member of Rugiet’s medical advisory board. “Rugiet’s TRT experience introduces a clinically-guided middle ground that is scalable and allows qualified patients to receive accessible care.”

The TRT launch coincides with a full-scale brand transformation designed to challenge the stale, boring, and homogeneous offerings within the category with a look that reimagines men’s healthcare. Created in collaboration with Pentagram on brand identity and Alright Studio on web design, Rugiet’s new look and feel nods to its clinical-rigor and confidence in its solutions, while reinforcing its commitment to Performance Medicine for Men.

For more information, visit rugiet.com/testosterone.

ABOUT RUGIET

Since 2020, Rugiet has combined clinical authority with innovative, personalized treatments to help more than 400,000 men take control of their health. From sexual health and sleep, to weight management and testosterone, we believe in not just fixing problems, but helping men optimize their health at every age. That's performance medicine for men. Learn more at www.rugiet.com.